Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) Q4 2018 Earnings Conference Call Transcript

Mar 05, 2019 • 09:00 am ET


Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) Q4 2018 Earnings Conference Call Transcript


Loading Event

Loading Transcript


Good morning and welcome to Dova Pharmaceutical's Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights Conference Call. All lines have been placed on mute to prevent any background noise. Following the speakers' remarks, there will be a question-and-answer session.

Before we begin, I would like to remind you that during today's call, statements about the Company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including those discussed in the factors -- in the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended December 31, 2018, which can be accessed on the EDGAR database at, and other filings that Company makes with the SEC from time-to-time.

In addition, any forward-looking statements represents the speakers' views only as of today and should not be relied upon as representing the speakers' or the Company's views as of any subsequent date. While the company may elect to update these forward-looking statements at some future point, the Company specifically disclaims any obligation to do so, even if the Company's views change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to today. Please be advised that today's conference call is being recorded and webcast.

I would now like to turn the call over to Dr. David Zaccardelli, Dova's President and CEO. David, you may begin your call.

David Zaccardelli

Thank you, operator, and good morning, everyone. Thank you for joining us on the call today. Joining me this morning are Mark Hahn, our Chief Financial Officer; Dr. Lee Allen, our Chief Medical Officer; Dr. Kevin Laliberte, our Senior Vice President of Product Development; and Jason Hoitt, our Chief Commercial Officer.

Since I joined in mid-December, we have spent a considerable time doing an in-depth analysis of our commercial strategy for DOPTELET. First, I want to highlight that this analysis has only increased our confidence in DOPTELET its significant market opportunity across multiple indications and, more importantly, the value it provides to patients. While this analysis had less -- has led us to make some changes to our commercial operation, it also has reinforced my belief that Dova has the people, products and resources necessary to provide important treatments for patients.

In terms of today's call, I'll begin by providing an update to our commercial efforts for DOPTELET starting with some detail on recent changes that are intended to improve the trajectory of sales in the chronic liver disease or CLD market, then I'll discuss several key launch metrics for the fourth quarter. Finally, I'll provide an update on our development programs with potential additional indications for DOPTELET, most notably our chronic immune thrombocytopenia or ITP program for which our supplemental new drug application is currently under review by the FDA, and our chemotherapy-induced thrombocytopenia or CIT program, which continues